A Phase 3 interventional study of Lenalidomide and low-dose dexamethasone and Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles in Multiple Myeloma, sponsored by Celgene. Completed at 288 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.
Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 3rd largest by enrollment, is one of 16 that started in 2008, is one of 44 in phase 3, and was the 47th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Dickran Kazandjian, MD · Sites in United States
University of Miami · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 164 · Phase 3 47 · Phase 4 10
First in 2002; this study’s year is marked. 16 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,623 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 249 interventional studies. Of the 155 that completed or were terminated, 81 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 249 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2008, is one of 30 in phase 3, and was the 24th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
14 of the studies testing lenalidomide in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 249 studies testing lenalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
CC-5013-MM020/IFM 07-01 is a Phase III, multicenter, randomized, open-label, 3-arm study that will compare the efficacy and safety of two Lenalidomide plus low-dose dexamethasone regimens given for two different durations of time (i.e., until progressive disease [PD] or for up to a maximum of 18 four-week cycles) to that of MPT given for a maximum of 12 six-week cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:
AND have by protein electrophoresis analyses as defined by the following:
AND are at least 65 years of age or older or, if younger than 65 years of age, are not candidates for stem cell transplantation because:
Females of (FCBP)\^2:
Male Patients:
All patients must:
Exclusion Criteria:
Any of the following laboratory abnormalities:
Prior history of , other than multiple myeloma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following:
Known positivity or active infectious hepatitis, type A, B, or C. Primary AL (immunoglobulin light chain) amyloidosis and myeloma complicated by amyloidosis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenalidomide plus low-dose dexamethasone given until disease progression
Drug: Lenalidomide and low-dose dexamethasone
Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
Drug: Melphalan, Prednisone and Thalidomide
Drug pages: Lenalidomide · Dexamethasone
Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
Also known as: Revlimid
Drug page: Lenalidomide
lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles
Also known as: Revlimid
Drug pages: Melphalan · Prednisone · Thalidomide
Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
Also known as: Prednisone, Thalomid
Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).
Time frame: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).
Time frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.
Time frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
Percentage of Participants With an Objective Response Based on IRAC Review
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.
Time frame: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
Time to First Response Based on the Review by the IRAC
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Time to First Response Based on the Investigator Assessment at the Time of Final Analysis
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
Kaplan Meier Estimates of Time to Treatment Failure (TTF)
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.
Time frame: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.
Time frame: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.
Time frame: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.
Time frame: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
Time frame: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Fatigue Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
Change From Baseline in the EORTC QLQ-C30 Pain Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Insomnia Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Constipation Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.
Time frame: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year
HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.
Time frame: Day 1 (randomization) up to last visit completed 25 July 2016
Number of Participants With Adverse Events (AEs) During the Active Treatment Phase
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.
Time frame: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.
Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
Time frame: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base
Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.
Time frame: From randomization to 24 May 2013
This study was conducted in the Europe, Asia, North America and Pacific regions. Participants were randomized at 246 sites (165 in Europe, 23 in Asia, 39 in North America, and 19 in the Pacific). The study was co-sponsored by Intergroupe Francophone du Myélome (IFM) (for sites in France, Switzerland, and Belgium) and Celgene Corporation.
| Milestone | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Started | 535 | 541 | 547 |
| Safety population | 532 | 540 | 541 |
| Untreated | 3 | 1 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 535 | 541 | 547 |
| Withdrew: Adverse event | 68 | 71 | 76 |
| Withdrew: Disease progression | 273 | 362 | 339 |
| Withdrew: Withdrawal by subject | 16 | 16 | 21 |
| Withdrew: Death | 60 | 28 | 37 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 |
| Withdrew: Protocol violation | 2 | 2 | 4 |
| Withdrew: Study close out | 64 | 26 | 21 |
| Withdrew: Miscellaneous | 52 | 34 | 47 |
| Milestone | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Started | 87 | 300 | 273 |
| Completed | 87 | 300 | 273 |
| Not completed | 0 | 0 | 0 |
| Milestone | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Started | 382 | 463 | 459 |
| Completed | 255 | 275 | 315 |
| Not completed | 127 | 188 | 144 |
| Withdrew: Continue in long term follow up | 127 | 188 | 144 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC) | 25.5 (20.7 to 29.4) | 20.7 (19.4 to 22.0) | 21.2 (19.3 to 23.2) |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's).
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis | 26.0 (20.7 to 29.7) | 21.0 (19.7 to 22.4) | 21.9 (19.8 to 23.9) |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS) | 59.1 (53.9 to 65.9) | 62.3 (53.6 to 68.7) | 49.1 (44.3 to 53.5) |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With an Objective Response Based on IRAC Review | 75.1 | 73.4 | 62.3 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis | 80.7 | 78.6 | 67.5 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC | 35.0 (27.9 to 43.4) | 22.1 (20.3 to 24.0) | 22.3 (20.2 to 24.9) |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis | 31.5 (26.2 to 37.3) | 21.5 (19.2 to 23.0) | 22.1 (20.3 to 24.5) |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Time to First Response Based on the Review by the IRAC | 1.8 (0.7 to 22.2) | 1.8 (0.8 to 17.1) | 2.8 (1.3 to 49.7) |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Time to First Response Based on the Investigator Assessment at the Time of Final Analysis | 1.8 (0.5 to 22.2) | 1.8 (0.8 to 34.8) | 2.8 (1.2 to 56.3) |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Time to Treatment Failure (TTF) | 16.9 (14.1 to 18.4) | 17.2 (14.6 to 18.2) | 14.1 (12.0 to 16.1) |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis | 16.9 (14.1 to 18.4) | 17.2 (14.6 to 18.2) | 14.1 (12.0 to 16.1) |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT) | 39.1 (32.8 to NA) | 28.5 (26.9 to 30.4) | 26.7 (24.0 to 29.9) |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.
| months | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis | 36.7 (31.9 to 45.2) | 28.5 (26.9 to 30.4) | 26.7 (24.0 to 29.1) |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis | 46.2 | 53.1 | 45.7 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| Percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review. | 70.0 | 69.7 | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review | 80.4 | 81.6 | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of particpants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review | 80.4 | 74.8 | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level \<100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to \<200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas.
| percentage of participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review | 60.5 | 76.8 | 57.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 0.4 ± 23.98 | -1.3 ± 23.93 | 1.0 ± 23.68 |
| Month 3 | 4.8 ± 24.15 | 4.7 ± 25.15 | 4.3 ± 26.04 |
| Month 6 | 5.9 ± 25.93 | 5.4 ± 23.88 | 6.1 ± 25.98 |
| Month 12 | 4.8 ± 26.42 | 3.2 ± 25.38 | 6.5 ± 25.90 |
| Month 18 | 6.4 ± 28.02 | 5.7 ± 24.86 | 4.8 ± 27.05 |
| Study discontinuation | -0.1 ± 27.07 | 5.0 ± 27.33 | 0.3 ± 28.07 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -1.7 ± 21.11 | -1.4 ± 19.56 | -0.9 ± 21.28 |
| Month 3 | 3.4 ± 23.33 | 4.7 ± 22.94 | 2.2 ± 23.68 |
| Month 6 | 4.7 ± 25.09 | 7.6 ± 22.85 | 5.3 ± 24.52 |
| Month 12 | 5.0 ± 25.65 | 7.4 ± 23.40 | 6.9 ± 27.22 |
| Month 18 | 6.9 ± 26.71 | 6.8 ± 23.58 | 8.3 ± 27.10 |
| Discontinuation Visit | -0.1 ± 29.70 | 3.0 ± 27.32 | -0.1 ± 27.58 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -2.7 ± 29.94 | -4.6 ± 28.20 | -2.4 ± 30.48 |
| Month 3 | 2.4 ± 33.32 | 6.3 ± 32.43 | 4.1 ± 34.23 |
| Month 6 | 6.3 ± 35.44 | 8.6 ± 32.42 | 8.2 ± 36.09 |
| Month 12 | 7.8 ± 36.60 | 9.4 ± 34.15 | 11.8 ± 38.94 |
| Month 18 | 8.0 ± 35.34 | 9.1 ± 34.35 | 14.5 ± 39.03 |
| Discontinuation Visit | -0.3 ± 39.58 | 3.8 ± 36.34 | -1.0 ± 38.41 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 0.6 ± 22.13 | 0.1 ± 20.73 | 1.0 ± 21.52 |
| Month 3 | 3.8 ± 22.29 | 3.9 ± 22.11 | 2.1 ± 22.27 |
| Month 6 | 4.6 ± 24.36 | 5.8 ± 22.39 | 5.5 ± 22.55 |
| Month 12 | 4.6 ± 24.08 | 4.9 ± 22.23 | 5.1 ± 22.37 |
| Month 18 | 5.8 ± 25.61 | 3.1 ± 23.31 | 5.1 ± 22.99 |
| Discontinuation Visit | 2.6 ± 24.30 | 3.7 ± 23.77 | -0.0 ± 24.72 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -1.2 ± 21.73 | -1.7 ± 19.08 | -1.8 ± 24.07 |
| Month 3 | -0.7 ± 22.89 | 1.8 ± 20.94 | -1.5 ± 24.02 |
| Month 6 | -0.9 ± 22.57 | 0.9 ± 19.77 | -0.3 ± 23.55 |
| Month 12 | -1.6 ± 25.05 | -1.2 ± 20.19 | -0.6 ± 22.97 |
| Month 18 | -2.2 ± 25.61 | -2.8 ± 20.97 | -0.7 ± 23.99 |
| Discontinuation Visit | -4.9 ± 27.57 | -2.6 ± 22.34 | -7.1 ± 25.15 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -4.3 ± 29.10 | -2.2 ± 27.44 | -1.4 ± 30.52 |
| Month 3 | 0.7 ± 29.36 | 2.0 ± 30.93 | 2.4 ± 30.70 |
| Month 6 | 4.0 ± 32.48 | 5.2 ± 28.50 | 3.4 ± 35.24 |
| Month 12 | 2.9 ± 34.96 | 3.8 ± 32.29 | 5.8 ± 33.68 |
| Month 18 | 4.2 ± 34.99 | 3.2 ± 31.67 | 6.0 ± 35.20 |
| Discontinuation Visit | -1.2 ± 33.50 | 2.7 ± 33.37 | -3.5 ± 33.20 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 2.6 ± 25.32 | 4.4 ± 24.03 | 2.8 ± 25.44 |
| Month 3 | -2.5 ± 28.15 | -3.4 ± 25.16 | -1.8 ± 28.53 |
| Month 6 | -3.7 ± 28.54 | -5.9 ± 26.37 | -4.5 ± 29.09 |
| Month 12 | -4.3 ± 29.47 | -2.3 ± 26.63 | -3.9 ± 29.56 |
| Month 18 | -3.1 ± 29.82 | 0.1 ± 29.12 | -4.3 ± 30.05 |
| Discontinuation Visit | 0.3 ± 29.75 | -1.6 ± 29.11 | 2.7 ± 30.15 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -5.4 ± 31.89 | -4.4 ± 30.70 | -7.8 ± 30.93 |
| Month 3 | -13.4 ± 34.28 | -13.1 ± 32.32 | -12.1 ± 31.98 |
| Month 6 | -14.4 ± 35.64 | -16.1 ± 33.44 | -13.4 ± 34.45 |
| Month 12 | -14.0 ± 36.05 | -14.7 ± 32.34 | -14.3 ± 32.85 |
| Month 18 | -14.4 ± 35.03 | -12.4 ± 35.28 | -14.7 ± 32.81 |
| Discontinuation Visit | -8.0 ± 39.37 | -7.9 ± 37.65 | -6.0 ± 37.09 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 1.8 ± 20.05 | -0.5 ± 23.19 | 4.0 ± 22.91 |
| Month 3 | -1.1 ± 19.42 | -2.5 ± 21.92 | -1.2 ± 19.89 |
| Month 6 | -1.3 ± 18.53 | -4.0 ± 21.52 | -3.9 ± 19.57 |
| Month 12 | -2.2 ± 17.16 | -3.6 ± 18.86 | -3.9 ± 19.09 |
| Month 18 | -2.3 ± 19.20 | -2.7 ± 18.92 | -3.9 ± 19.44 |
| Discontinuation Visit | 0.4 ± 21.43 | -4.2 ± 24.37 | 1.0 ± 21.46 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 0.9 ± 30.87 | 3.6 ± 29.85 | 4.2 ± 32.04 |
| Month 3 | -0.8 ± 31.87 | -1.9 ± 29.45 | 2.0 ± 32.49 |
| Month 6 | -2.3 ± 33.12 | -2.9 ± 29.66 | 0.1 ± 30.29 |
| Month 12 | -3.5 ± 30.97 | -1.6 ± 29.23 | -1.6 ± 32.76 |
| Month 18 | -1.8 ± 32.73 | 2.9 ± 28.33 | 0.4 ± 32.68 |
| Discontinuation Visit | -1.0 ± 37.42 | 0.8 ± 31.01 | 7.8 ± 33.72 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 2.1 ± 33.34 | 3.2 ± 34.32 | -10.5 ± 30.47 |
| Month 3 | 0.2 ± 35.11 | -1.3 ± 33.54 | -8.9 ± 35.28 |
| Month 6 | -1.2 ± 34.84 | -1.9 ± 31.43 | -11.6 ± 32.96 |
| Month 12 | -1.0 ± 34.78 | 1.1 ± 32.47 | -9.6 ± 31.00 |
| Month 18 | -0.5 ± 37.11 | 1.4 ± 35.72 | -6.0 ± 34.42 |
| Discontinuation Visit | -5.2 ± 36.47 | -1.6 ± 31.27 | -4.5 ± 36.98 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 1.3 ± 33.46 | 2.9 ± 31.87 | 1.0 ± 32.35 |
| Month 3 | -5.9 ± 38.34 | -3.3 ± 35.25 | -6.2 ± 35.03 |
| Month 6 | -9.8 ± 40.02 | -8.6 ± 33.98 | -13.5 ± 35.98 |
| Month 12 | -7.3 ± 37.07 | -6.4 ± 35.30 | -10.5 ± 34.16 |
| Month 18 | -8.1 ± 35.97 | -5.1 ± 33.29 | -12.2 ± 31.88 |
| Discontinuation Visit | -1.0 ± 36.77 | -7.5 ± 37.49 | -2.6 ± 37.18 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 8.3 ± 36.74 | 6.3 ± 36.18 | 18.4 ± 41.23 |
| Month 3 | 1.8 ± 37.53 | 0.0 ± 37.02 | 13.9 ± 39.30 |
| Month 6 | -2.4 ± 37.51 | -5.1 ± 37.39 | 6.8 ± 40.41 |
| Month 12 | -2.4 ± 38.79 | -5.2 ± 38.09 | 3.7 ± 38.28 |
| Month 18 | -4.5 ± 35.42 | -5.9 ± 36.65 | 0.0 ± 37.06 |
| Discontinuation Visit | -7.9 ± 39.98 | -7.5 ± 39.20 | -2.2 ± 38.86 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 3.8 ± 25.53 | 2.3 ± 24.94 | -0.6 ± 18.79 |
| Month 3 | 3.7 ± 24.99 | 3.4 ± 27.27 | -2.4 ± 18.61 |
| Month 6 | 8.2 ± 28.36 | 6.0 ± 27.95 | -2.2 ± 21.19 |
| Month 12 | 11.8 ± 31.35 | 9.1 ± 28.74 | -2.5 ± 17.26 |
| Month 18 | 14.8 ± 31.20 | 10.9 ± 30.96 | -1.7 ± 17.46 |
| Discontinuation Visit | 10.8 ± 29.56 | 6.4 ± 31.38 | -0.5 ± 19.39 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 2.1 ± 21.43 | -0.3 ± 20.59 | 0.5 ± 22.98 |
| Month 3 | 1.9 ± 23.09 | -0.4 ± 21.88 | 1.9 ± 21.48 |
| Month 6 | 1.4 ± 22.92 | -0.3 ± 21.24 | 0.7 ± 24.57 |
| Month 12 | 0.4 ± 23.99 | 1.6 ± 23.28 | 1.1 ± 23.16 |
| Month 18 | 2.0 ± 22.23 | 1.8 ± 23.30 | 0.4 ± 21.20 |
| Discontinuation Visit | 1.9 ± 27.19 | 0.5 ± 23.84 | 5.0 ± 24.82 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s).
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -4.0 ± 18.75 | -4.1 ± 19.37 | -4.4 ± 19.04 |
| Month 3 | -9.1 ± 21.66 | -10.0 ± 19.97 | -7.0 ± 20.43 |
| Month 6 | -8.8 ± 20.89 | -9.9 ± 20.94 | -7.9 ± 21.94 |
| Month 12 | -7.8 ± 21.74 | -8.7 ± 20.29 | -6.5 ± 21.58 |
| Month 18 | -8.7 ± 23.50 | -6.2 ± 23.30 | -7.9 ± 21.26 |
| Discontinuation Visit | -3.5 ± 24.82 | -4.5 ± 24.90 | -3.7 ± 23.54 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 2.5 ± 13.72 | 4.0 ± 14.89 | 5.6 ± 15.00 |
| Month 3 | 1.0 ± 15.23 | 1.2 ± 14.67 | 3.5 ± 15.40 |
| Month 6 | 1.7 ± 15.58 | -0.4 ± 14.39 | 2.9 ± 17.28 |
| Month 12 | 1.9 ± 14.49 | 1.2 ± 16.20 | 4.7 ± 17.17 |
| Month 18 | 2.2 ± 15.63 | 2.3 ± 17.36 | 4.3 ± 16.37 |
| Discontinuation Visit | 0.6 ± 15.85 | -1.0 ± 15.81 | 3.8 ± 16.52 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 4.7 ± 22.17 | 3.9 ± 20.94 | 3.3 ± 23.20 |
| Month 3 | 8.5 ± 23.28 | 9.2 ± 22.95 | 6.3 ± 25.06 |
| Month 6 | 9.8 ± 23.67 | 12.3 ± 24.84 | 8.0 ± 25.26 |
| Month 12 | 10.8 ± 21.90 | 12.1 ± 24.41 | 10.0 ± 26.30 |
| Month 18 | 12.7 ± 23.96 | 11.7 ± 24.76 | 9.5 ± 21.75 |
| Discontinuation Visit | 5.8 ± 25.91 | 8.8 ± 26.71 | 3.2 ± 27.13 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | -4.5 ± 29.44 | -1.5 ± 27.19 | -1.6 ± 29.97 |
| Month 3 | -1.7 ± 27.54 | 0.8 ± 26.23 | -3.0 ± 29.38 |
| Month 6 | -1.4 ± 27.84 | 1.5 ± 29.72 | -2.8 ± 33.07 |
| Month 12 | -1.4 ± 29.60 | -0.4 ± 31.64 | -2.6 ± 31.96 |
| Month 18 | -2.3 ± 28.09 | -0.3 ± 31.04 | -1.1 ± 33.60 |
| Discontinuation Visit | -5.6 ± 34.29 | 1.8 ± 30.66 | -5.6 ± 33.73 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state.
| units on a scale | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Month 1 | 0.0 ± 0.29 | -0.0 ± 0.31 | 0.0 ± 0.28 |
| Month 3 | 0.1 ± 0.33 | 0.1 ± 0.32 | 0.1 ± 0.32 |
| Month 6 | 0.1 ± 0.32 | 0.1 ± 0.31 | 0.1 ± 0.34 |
| Month 12 | 0.1 ± 0.33 | 0.1 ± 0.31 | 0.1 ± 0.35 |
| Month 18 | 0.1 ± 0.36 | 0.1 ± 0.32 | 0.1 ± 0.35 |
| Discontinuation Visit | 0.0 ± 0.40 | 0.0 ± 0.35 | 0.0 ± 0.39 |
HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU Analysis may help in evaluating potential costs and budget impact of new treatments from a payer perspective. The rate of inpatient hospitalizations per patient year was calculated as the total number of hospitalizations divided by the total number of patient-years followed in the study period. Patient-years (PY) were calculated as the duration from baseline to last available HRQL assessment for each patient.
No measurements were reported for this outcome.
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event.
| Participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| ≥ 1 adverse event (AE) | 529 | 536 | 539 |
| ≥ 1 grade (Gr) 3 or 4 AE | 453 | 433 | 480 |
| ≥ 1 grade (Gr) 5 AE | 50 | 36 | 38 |
| ≥ 1 serious adverse event (SAE) | 359 | 308 | 270 |
| ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | 506 | 501 | 527 |
| ≥ 1 AE related to Lenalidomide | 482 | 481 | 0 |
| ≥ 1 AE related to dexamethasone | 429 | 410 | 0 |
| ≥ 1 AE related to melphalan | 0 | 0 | 441 |
| ≥ 1 AE related to prednisone | 0 | 0 | 326 |
| ≥ 1 AE related to thalidomide | 0 | 0 | 493 |
| ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | 269 | 269 | 145 |
| ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | 373 | 326 | 423 |
| ≥ 1 grade 3 or 4 AE related to Lenalidomide | 342 | 290 | 0 |
| ≥ 1 grade 3 or 4 AE related to dexamethasone | 229 | 177 | 0 |
| ≥ 1 grade 3 or 4 AE related to melphalan | 0 | 0 | 307 |
| ≥ 1 grade 3 or 4 AE related to prednisone | 0 | 0 | 118 |
| ≥ 1 grade 3 or 4 AE related to Thalidomide | 0 | 0 | 316 |
| ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | 131 | 104 | 49 |
| ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | 17 | 11 | 10 |
| ≥ 1 Grade 5 AE related to Lenalidomide | 12 | 9 | 0 |
| ≥ 1 Grade 5 AE related to Dexamethasone | 16 | 7 | 0 |
| ≥ 1 Grade 5 AE related to melphalan | 0 | 0 | 6 |
| ≥ 1 Grade 5 AE related to prednisone | 0 | 0 | 5 |
| ≥ 1 Grade 5 AE related to Thalidomide | 0 | 0 | 5 |
| ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | 11 | 5 | 2 |
| ≥1 SAE related to Len/Dex/Mel/Pred/Thal | 195 | 158 | 142 |
| ≥1 SAE related to Lenalidomide | 165 | 130 | 0 |
| ≥1 SAE related to dexamethasone | 130 | 97 | 0 |
| ≥1 SAE related to melphalan | 0 | 0 | 75 |
| ≥1 SAE related to prednisone | 0 | 0 | 62 |
| ≥1 SAE related to thalidomide | 0 | 0 | 94 |
| ≥1 SAE related to Len/Dex or Mel/Pred/Thal | 95 | 64 | 27 |
| ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | 157 | 109 | 153 |
| ≥1 AE leading to Lenalidomide withdrawal | 109 | 93 | 0 |
| ≥1 AE leading to dexamethasone withdrawal | 152 | 104 | 0 |
| ≥1 AE leading to melphalan withdrawal | 0 | 0 | 83 |
| ≥1 AE leading to prednisone withdrawal | 0 | 0 | 78 |
| ≥1 AE leading to Thalidomide withdrawal | 0 | 0 | 146 |
| ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | 96 | 84 | 71 |
| ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | 279 | 214 | 348 |
| ≥1 AE leading to Lenalidomide reduction | 203 | 155 | 0 |
| ≥1 AE leading to dexamethasone reduction | 170 | 118 | 0 |
| ≥1 AE leading to melphalan reduction | 0 | 0 | 199 |
| ≥1 AE leading to prednisone reduction | 0 | 0 | 47 |
| ≥1 AE leading to thalidomide reduction | 0 | 0 | 254 |
| ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | 30 | 20 | 2 |
| ≥1 AE leading to Rd or MPT interruption | 368 | 321 | 419 |
| ≥1 AE leading to Lenalidomide interruption | 353 | 301 | 0 |
| ≥1 AE leading to dexamethasone interruption | 319 | 280 | 0 |
| ≥1 AE leading to melphalan interruption | 0 | 0 | 328 |
| ≥1 AE leading to prednisone interruption | 0 | 0 | 324 |
| ≥1 AE leading to Thalidomide interruption | 0 | 0 | 388 |
| ≥1 AE leading to Len and Dex or MPT interruption | 290 | 241 | 249 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.
| participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| CrCl< 30 mL/min to CrCl< 30 mL/min | 15 | 17 | 19 |
| CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | 18 | 14 | 19 |
| CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | 7 | 8 | 5 |
| CrCl< 30 mL/min to ≥ 80 mL/min | 2 | 2 | 0 |
| CrCl≥ 30 but < 50 mL/min to < 30 mL/min | 1 | 2 | 0 |
| CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | 37 | 41 | 41 |
| CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | 67 | 55 | 65 |
| CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | 9 | 12 | 2 |
| CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | 0 | 0 | 0 |
| CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | 4 | 1 | 4 |
| CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | 112 | 130 | 102 |
| CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | 107 | 99 | 97 |
| CrCl ≥ 80 mL/min to CrCl< 30 mL/min | 0 | 1 | 0 |
| CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | 0 | 0 | 0 |
| CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | 6 | 10 | 9 |
| CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | 109 | 114 | 121 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
| participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | 103 | 133 | 37 |
| Normal Baseline Grade to Grade 1 postbaseline | 96 | 85 | 79 |
| Normal Baseline Grade to Grade 2 postbaseline | 121 | 109 | 128 |
| Normal Baseline Grade to Grade 3 postbaseline | 70 | 71 | 141 |
| Normal Baseline Grade to Grade 4 postbaseline | 21 | 30 | 45 |
| Grade 1 Baseline to Normal postbaseline | 7 | 6 | 2 |
| Grade1 Baseline to Grade 1 postbaseline | 8 | 11 | 2 |
| Grade 1 Baseline to Grade 2 postbaseline | 17 | 15 | 11 |
| Grade 1 Baseline to Grade 3 postbaseline | 25 | 30 | 20 |
| Grade 1 Baseline to Grade 4 postbaseline | 9 | 4 | 21 |
| Grade 2 Baseline to normal postbaseline | 1 | 0 | 0 |
| Grade 2 Baseline to Grade 1 postbaseline | 1 | 1 | 1 |
| Grade 2 Baseline to Grade 2 postbaseline | 14 | 11 | 7 |
| Grade 2 Baseline to Grade 3 postbaseline | 18 | 18 | 21 |
| Grade 2 Baseline to Grade 4 postbaseline | 9 | 5 | 10 |
| Grade 3 Baseline to Normal postbaseline | 0 | 0 | 0 |
| Grade 3 Baseline to Grade 1 postbaseline | 0 | 0 | 0 |
| Grade 3 Baseline to Grade 2 postbaseline | 2 | 1 | 0 |
| Grade 3 Baseline to Grade 3 postbaseline | 2 | 2 | 0 |
| Grade3 Baseline to Grade 4 postbaseline | 0 | 2 | 1 |
| Grade 4 Baseline to Normal postbaseline Grade | 0 | 0 | 0 |
| Grade 4 Baseline to Grade 1 postbaseline Grade | 1 | 0 | 0 |
| Grade 4 Baseline to Grade 2 postbaseline | 0 | 0 | 0 |
| Grade 4 Baseline Grade to Grade 3 postbaseline | 0 | 0 | 0 |
| Grade 4 Baseline to Grade 4 postbaseline | 0 | 0 | 0 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
| participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | 6 | 10 | 9 |
| Normal Baseline Grade to Grade 1 postbaseline | 39 | 30 | 25 |
| Normal Baseline Grade to Grade 2 postbaseline | 8 | 8 | 4 |
| Normal Baseline Grade to Grade 3 postbaseline | 0 | 1 | 1 |
| Normal Baseline Grade to Grade 4 postbaseline | 0 | 0 | 0 |
| Grade 1 Baseline to Normal postbaseline | 0 | 0 | 0 |
| Grade 1 Baseline to Grade 1 postbaseline | 106 | 126 | 110 |
| Grade1 Baseline to Grade 2 postbaseline | 128 | 123 | 123 |
| Grade 1 Baseline to Grade 3 postbaseline | 25 | 17 | 20 |
| Grade 1 Baseline to Grade 4 postbaseline | 2 | 5 | 4 |
| Grade 2 Baseline to normal postbaseline | 0 | 0 | 0 |
| Grade 2 Baseline to Grade 1 postbaseline | 8 | 12 | 14 |
| Grade 2 Baseline to Grade 2 postbaseline | 125 | 135 | 133 |
| Grade 2 Baseline to Grade 3 postbaseline | 48 | 41 | 47 |
| Grade 2 Baseline to Grade 4 postbaseline | 4 | 9 | 11 |
| Grade 3 Baseline to Normal postbaseline | 0 | 0 | 0 |
| Grade 3 Baseline to Grade 1 postbaseline | 0 | 1 | 0 |
| Grade 3 Baseline to Grade 2 postbaseline | 12 | 4 | 10 |
| Grade 3 Baseline to Grade 3 postbaseline | 10 | 8 | 10 |
| Grade 3 Baseline to Grade 4 postbaseline | 5 | 3 | 2 |
| Grade 4 Baseline to Normal postbaseline | 0 | 0 | 0 |
| Grade 4 Baseline to Grade 1 postbaseline | 0 | 0 | 0 |
| Grade 4 Baseline to Grade 2 postbaseline | 0 | 0 | 1 |
| Grade 4 Baseline to Grade 3 postbaseline | 0 | 1 | 0 |
| Grade 4 Baseline to Grade 4 postbaseline | 1 | 1 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale.
| participants | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | 197 | 197 | 165 |
| Normal Baseline Grade to Grade 1 postbaseline | 216 | 211 | 208 |
| Normal Baseline Grade to Grade 2 postbaseline | 24 | 30 | 27 |
| Normal Baseline Grade to Grade 3 postbaseline | 15 | 12 | 31 |
| Normal Baseline Grade to Grade 4 postbaseline | 4 | 5 | 11 |
| Grade1 Baseline to Normal postbaseline Grade | 1 | 3 | 6 |
| Grade 1 Baseline to Grade 1 postbaseline | 34 | 38 | 51 |
| Grade 1 Baseline to Grade 2 postbaseline | 15 | 19 | 7 |
| Grade 1 Baseline to Grade 3 postbaseline | 10 | 12 | 10 |
| Grade 1 Baseline to Grade 4 postbaseline | 2 | 1 | 1 |
| Grade 2 Baseline to normal postbaseline Grade | 0 | 0 | 0 |
| Grade 2 Baseline to Grade 1 postbaseline | 0 | 1 | 2 |
| Grade 2 Baseline to Grade 2 postbaseline | 3 | 3 | 1 |
| Grade 2 Baseline to Grade 3 postbaseline | 3 | 2 | 2 |
| Grade 2 Baseline to Grade 4 postbaseline | 1 | 0 | 2 |
| Grade 3 Baseline to Normal postbaseline Grade | 0 | 0 | 0 |
| Grade 3 Baseline to Grade 1 postbaseline | 0 | 0 | 0 |
| Grade 3 Baseline to Grade 2 postbaseline | 0 | 0 | 1 |
| Grade 3 Baseline to Grade 3 postbaseline | 0 | 0 | 1 |
| Grade 3 Baseline to Grade 4 postbaseline | 2 | 1 | 0 |
Improvement of infection rate by observing historical data compared to the data within clinical database as not analyzed.
No measurements were reported for this outcome.
Collected over From the first dose of treatment to at least 28 days after discontinuation of active treatment for those not continuing in the PFS phase; median duration of treatment was 80.2 weeks in the Rd arm, 72.0 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | — | 378/532 (71.1%) | 523/532 (98.3%) |
| Lenalidomide and Dexamethasone (Rd18) | — | 308/540 (57%) | 532/540 (98.5%) |
| Melphalan + Prednisone + Thalidomide (MPT) | — | 270/541 (49.9%) | 532/541 (98.3%) |
| Event | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone (Rd18) | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 60/532 | 48/540 | 35/541 |
| ANAEMIABlood and lymphatic system disorders | 24/532 | 15/540 | 23/541 |
| PYREXIAGeneral disorders | 22/532 | 11/540 | 8/541 |
| BACK PAINMusculoskeletal and connective tissue disorders | 22/532 | 19/540 | 10/541 |
| RENAL FAILURE ACUTERenal and urinary disorders | 21/532 | 16/540 | 10/541 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 20/532 | 15/540 | 20/541 |
| DEEP VEIN THROMBOSISVascular disorders | 19/532 | 11/540 | 8/541 |
| ATRIAL FIBRILLATIONCardiac disorders | 18/532 | 12/540 | 9/541 |
| RENAL FAILURERenal and urinary disorders | 8/532 | 18/540 | 14/541 |
| SEPSISInfections and infestations | 17/532 | 10/540 | 8/541 |
| Event | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone (Rd18) | Melphalan + Prednisone + Thalidomide (MPT) |
|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 194/532 | 177/540 | 325/541 |
| CONSTIPATIONGastrointestinal disorders | 233/532 | 210/540 | 282/541 |
| DIARRHOEAGastrointestinal disorders | 248/532 | 205/540 | 86/541 |
| ANAEMIABlood and lymphatic system disorders | 237/532 | 191/540 | 219/541 |
| OEDEMA PERIPHERALGeneral disorders | 220/532 | 168/540 | 213/541 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 113/532 | 93/540 | 191/541 |
| FATIGUEGeneral disorders | 178/532 | 176/540 | 153/541 |
| BACK PAINMusculoskeletal and connective tissue disorders | 175/532 | 137/540 | 115/541 |
| NAUSEAGastrointestinal disorders | 156/532 | 127/540 | 163/541 |
| INSOMNIAPsychiatric disorders | 150/532 | 127/540 | 53/541 |
Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not
| Age, Continuous(years) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| Mean | 73.2 ± 6.57 | 72.9 ± 6.50 | 73.1 ± 6.32 | 73.1 ± 6.46 |
| Sex: Female, Male(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| Female | 241 | 268 | 260 | 769 |
| Male | 294 | 273 | 287 | 854 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| Asian | 40 | 43 | 44 | 127 |
| Black or African American | 9 | 6 | 5 | 20 |
| Native Hawaiian or other Pacific Islanders | 1 | 0 | 1 | 2 |
| White or Caucasian | 474 | 480 | 491 | 1445 |
| Other, Miscellaneous | 6 | 11 | 3 | 20 |
| Undisclosed | 5 | 1 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 37 | 33 | 36 | 106 |
| Not Hispanic or Latino | 493 | 505 | 508 | 1506 |
| Undisclosed | 5 | 3 | 3 | 11 |
| International Staging System (ISS)(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| Stage I | 106 | 106 | 103 | 315 |
| Stage II | 227 | 229 | 225 | 681 |
| Stage III | 202 | 206 | 219 | 627 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| 0 (fully active) | 155 | 163 | 156 | 474 |
| 1 (restrictive but ambulatory) | 257 | 263 | 275 | 795 |
| 2 (ambulatory but unable to work) | 119 | 113 | 111 | 343 |
| 3-4 (limited self-care, completely disabled) | 2 | 2 | 2 | 6 |
| Missing | 2 | 0 | 3 | 5 |
| Creatinine clearance(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| >=60 ml/min | 269 | 280 | 285 | 834 |
| <60 ml/min | 266 | 261 | 261 | 788 |
| Missing | 0 | 0 | 1 | 1 |
| Beta2 Microglobulin(Participants) | Lenalidomide and Low-Dose Dexamethasone (Rd) | Lenalidomide and Dexamethasone Rd18 | Melphalan + Prednisone + Thalidomide (MPT) | Total |
|---|---|---|---|---|
| >5.5 mg/L | 224 | 224 | 234 | 682 |
| <=5.5 mg/L | 309 | 316 | 312 | 937 |
| Missing | 2 | 1 | 1 | 4 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 288 sites across 19 countries. Choose a country and city above to see the rest.
Ran from Aug 2008 to primary completion in Jul 2016, 94 months.
Results were first posted in Aug 2017, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 94 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Dexamethasone